NCT05800444View on ClinicalTrials.gov

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions
Chronic Kidney DiseaseHealthy Volunteers
Interventions
DRUG

BAY3283142

Oral administration as tablet.

OTHER

Placebo

Oral administration as tablet.

Trial Locations (1)

813-0017

SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05800444 - A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants | Biotech Hunter | Biotech Hunter